- Parents of kids aged 0-5 will have to wait until at least April for a COVID-19 vaccine.
- On Friday Pfizer said it was going to “wait for the 3-dose data” before requesting FDA authorization.
- Pfizer says a 3-dose regimen may provide better protection than 2 doses.
Pfizer announced on Friday that the company will continue to “wait for the three-dose data” from its COVID-19 vaccine trial in kids 6 months to 5 years of age, before submitting for an Emergency Use Authorization with the US Food and Drug Administration.
“Given that the study is advancing at a rapid pace, the companies will wait for the three-dose data as Pfizer and BioNTech continue to believe it may provide a higher level of protection in this age group,” the pharmaceutical company said in a release. “The companies expect to have three-dose protection data available in early April.”
The FDA’s independent advisory group was set to meet next week to review the data, but that meeting will now be put on hold for at least several more weeks.
This is a developing story, check back for updates.
